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Abstract 28 
 29 
The purpose of this study was to test the hypothesis that inorganic nitrate (NO3
-
) 30 
supplementation would improve muscle oxygenation, pulmonary O2 uptake ( O2) kinetics 31 
and exercise tolerance (Tlim) to a greater extent when cycling at high compared low pedal 32 
rates.  In a randomised, placebo-controlled, cross-over study, seven subjects (mean ± SD, age 33 
21 ± 2 yr, body mass 86 ± 10 kg) completed severe-intensity step cycle tests at pedal 34 
cadences of 35 rpm and 115 rpm during separate 9 day supplementation periods with NO3
-
-35 
rich beetroot juice (BR; providing 8.4 mmol NO3
-∙day-1) and placebo (PLA).  Compared to 36 
PLA, plasma nitrite concentration increased 178% with BR (P<0.01).  There were no 37 
significant differences in muscle oxyhemoglobin concentration ([O2Hb]), phase II O2 38 
kinetics or Tlim between BR and PLA when cycling at 35 rpm (P>0.05).  However, when 39 
cycling at 115 rpm, muscle [O2Hb] was higher at baseline and throughout exercise, phase II 40 
O2 kinetics was faster (47 ± 16 s vs. 61 ± 25 s; P<0.05) and Tlim was greater (362 ± 137 s 41 
vs. 297 ± 79 s; P<0.05) with BR compared to PLA.  In conclusion, these results suggest that 42 
short-term BR supplementation can increase muscle oxygenation, expedite the adjustment of 43 
oxidative metabolism and enhance exercise tolerance when cycling at a high, but not a low, 44 
pedal cadence in healthy recreationally-active subjects.  These findings support recent 45 
observations that NO3
-
 supplementation may be particularly effective at improving 46 
physiological and functional responses in type II muscle fibers.      47 
 48 
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Introduction 62 
 63 
Nitric oxide (NO) is a diffusible gas that positively impacts a plethora of physiological 64 
responses including skeletal muscle perfusion, metabolism, force production and fatigue 65 
resistance (53).  It is well documented that NO is produced by the nitric oxide synthase 66 
enzymes, which catalyze the complex five-electron oxidation of the semi-essential amino 67 
acid, L-arginine (10).  More recently, there has been a growing appreciation of the potential 68 
for NO synthesis from the simple one-electron reduction of nitrite (NO2
-
), in a reaction 69 
catalyzed by numerous NO2
-
 reductases (42, 54).  Importantly, increasing the intake of 70 
dietary inorganic nitrate (NO3
-
), which passes into the enterosalivary circulation for 71 
subsequent reduction to NO2
-
 by oral anaerobes (20), has been shown to positively impact 72 
NO biomarkers, exercise efficiency and exercise tolerance in recreationally active subjects 73 
(3-4, 12, 40-41, 55, 58).  Therefore, supplementation with NO3
-
 appears to represent an 74 
effective dietary intervention to improve NO bioavailability, contractile efficiency, and 75 
fatigue resistance. 76 
 77 
Results from in vitro studies suggest that the effect of NO donors on mammalian skeletal 78 
muscle contractility is influenced by contraction frequency (5, 21, 43, 46).  Hernandez et al. 79 
(33) harvested whole EDL muscles and single FDB muscle fibers from NO3
-
 supplemented 80 
mice and reported increased in vitro contractile force up to 50 Hz stimulation and a more 81 
rapid rate of force development in the single FDB muscle fibers at 100 Hz stimulation.  82 
Similarly, increased evoked contractile force has been observed in human skeletal muscle in 83 
vivo during low-frequency sub-maximal stimulation and over the initial stages of high-84 
frequency maximal stimulation following NO3
-
 supplementation (29).  However, NO3
-
 85 
ingestion has been shown to increase human peak knee extensor torque at 360°·s
-1
, but not 86 
90°·s
-1
, 180°·s
-1
 and 270°·s
-1
, in vivo (16).  Collectively, these findings suggest that dietary 87 
NO3
-
 supplementation enhances skeletal muscle contractile function, and that it might be 88 
particularly effective at augmenting contractility at higher contraction velocities.  However, 89 
heretofore, human in vivo studies reporting improvements in exercise tolerance following 90 
NO3
-
 supplementation have utilized cycle ergometer exercise with pedal cadences of 70-90 91 
rpm (i.e., at “mid-range” contraction frequency/velocity; e.g., see 4, 12, 55, 58).  92 
Consequently, it is unclear whether NO3
-
 supplementation may be more effective at 93 
improving skeletal muscle fatigue resistance at a higher contraction frequency/velocity. 94 
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Relative to a lower contraction frequency (60 rpm), a higher contraction frequency (100 rpm) 95 
has been shown to increase O2 and to reduce contractile efficiency in human skeletal muscle 96 
in vivo (22).  Similarly, when contraction duration is shortened, O2 (30, 34) and the ATP 97 
cost of force production (34) are increased in mammalian skeletal muscle in situ relative to 98 
contractions of longer duration when the same work-rest ratio is applied.  There is also 99 
evidence to suggest that pulmonary O2 kinetics is slower (11, 19) and the O2 slow 100 
component is increased (11, 49) when cycling at very high compared to very low pedal 101 
cadences.  Dietary NO3
-
 supplementation has been shown to increase muscle blood flow (23), 102 
lower the O2 (3-4, 40-41, 55, 58) and ATP (3) requirements of muscle contraction and 103 
improve the matching between muscle O2 supply and muscle O2 utilization (4, 24).  104 
Therefore, this potential for enhanced contractile efficiency and perfusion distribution with 105 
NO3
-
 supplementation might improve muscle oxygenation, O2 kinetics and exercise 106 
tolerance, particularly when more rapid muscle contractions are completed.       107 
 108 
In addition to compromising muscle contractile efficiency, it has been suggested that the 109 
proportional contribution of fast-twitch muscle fibers to force production is greater at higher 110 
pedal cadences (6-7, but see 1).  Importantly, dietary NO3
-
 supplementation has been shown, 111 
at least in rodent models, to: 1) increase bulk muscle blood flow and preferentially distribute 112 
this towards fast-twitch muscle fibers (23); and 2) increase calcium handling proteins and 113 
twitch and tetanic force production in fast-twitch muscle, but not in slow-twitch muscle (33).  114 
In support of a targeted effect of NO3
-
 supplementation on fast-twitch muscle, Breese et al. 115 
(12) have recently reported that NO3
-
 supplementation speeds oxygen uptake ( O2) and 116 
muscle deoxyhemoglobin (HHb; reflective of the balance between muscle O2 utilization and 117 
muscle O2 delivery [25, 36]) kinetics during a severe-intensity step exercise test initiated 118 
from a moderate-intensity baseline.  Conversely, there was no effect when a moderate-119 
intensity step test was initiated from a low-intensity baseline.  This is important because, 120 
compared to the latter, the former would be expected to involve a greater recruitment of fast-121 
twitch fibers (37-38).  Taken together, these findings suggest that dietary NO3
-
 122 
supplementation may preferentially augment physiological responses within, and in the 123 
miscrovasculature surrounding, fast-twitch muscle fibers.  Based on these observations, the 124 
effects of NO3
-
 might be more pronounced when humans cycle at a very high compared to a 125 
very low pedal cadence; however, this has yet to be investigated. 126 
 127 
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The purpose of this study was to evaluate the effects of short term dietary NO3
-
 128 
supplementation on muscle oxygenation, pulmonary O2 kinetics and exercise tolerance 129 
when cycling at a very high (115 rpm) and a very low (35 rpm) pedal cadence at the same 130 
relative exercise intensity.  Given the effects of cadence on the physiological responses 131 
evoked during cycling and the physiological benefits afforded by NO3
-
 supplementation (see 132 
above), we hypothesized that muscle oxygenation, pulmonary O2 kinetics and exercise 133 
tolerance would be improved to a greater extent with NO3
-
 when cycling at 115 rpm than at 134 
35 rpm.   135 
 136 
Methods 137 
 138 
Subjects 139 
Seven healthy male subjects (mean ± SD age, 21 ± 2 yrs; body mass, 86 ± 10 kg; height, 1.82 140 
± 0.08 m) volunteered to participate in this study.   None of the subjects were tobacco 141 
smokers or users of dietary supplements.  The subjects participated in exercise at a 142 
recreational level, but were not highly trained.  All subjects were familiar with laboratory 143 
exercise testing procedures, having previously participated in studies employing cycle 144 
ergometry in our laboratory.  The procedures employed in this study were approved by the 145 
Institutional Research Ethics Committee and all subjects were required to give their written 146 
informed consent prior to the commencement of the study after the experimental procedures, 147 
associated risks, and potential benefits of participation had been explained.  Subjects were 148 
instructed to arrive at the laboratory in a rested and fully hydrated state, at least 3 h 149 
postprandial, and to avoid strenuous exercise in the 24 h preceding each testing session.  All 150 
tests were performed at the same time of day (± 2 h).  Each subject was asked to refrain from 151 
caffeine and alcohol intake for 6 h and 24 h before each test, respectively.  Subjects were also 152 
provided with a list of foods rich in NO3
-
 and instructed to avoid the consumption of these 153 
foods and to abstain from the use of antibacterial mouthwash, which eliminates the oral 154 
bacteria that reduce NO3
-
 to NO2
-
 (26), for the duration of the study.   155 
 156 
Experimental Design 157 
Subjects were required to report to the laboratory on 10 occasions over a 5-7 week timeframe.  158 
Prior to the experimental testing, subjects completed cadence-specific ramp incremental tests 159 
at 35 and 115 rpm in a randomised order so that the same relative exercise intensity could be 160 
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prescribed at both pedal cadences during the experimental tests.  Over the remaining eight 161 
laboratory visits, subjects completed severe-intensity step exercise tests at 35 and 115 rpm 162 
during separate 9-day supplementation periods with BR (35-BR and 115-BR, respectively) 163 
and PLA (35-PLA and 115-PLA, respectively) for determination of heart rate (HR), stroke 164 
volume (SV), cardiac output (?̇?), muscle oxygenation, O2 kinetics and exercise tolerance.  165 
The two supplementation periods were administered as part of a randomised (3 subjects 166 
started on BR), cross-over, double-blinded experimental design.   167 
 168 
Incremental Tests 169 
Before the intervention period, subjects completed a ramp incremental test at 35 and 115 rpm 170 
on an electronically-braked cycle ergometer (Lode Excalibur Sport, Groningen, the 171 
Netherlands) in a randomized order.  At least 48 hours separated the two ramp incremental 172 
tests.  Initially, subjects performed 3 min of baseline cycling at 20 W, after which the work 173 
rate was increased by 30 W/min until the limit of tolerance. The saddle and handle bar height 174 
and configuration during the first incremental test was recorded and reproduced in subsequent 175 
tests.  During the baseline period and the incremental test, subjects cycled at a pre-determined 176 
pedal rate (either 35 or 115 rpm) until volitional exhaustion or the cadence fell by > 10 rpm 177 
for 3 consecutive seconds.  Breath-by-breath pulmonary gas-exchange data were collected 178 
continuously during the incremental tests and averaged over consecutive 10-s periods.  The 179 
o2max was taken as the highest 30-s mean value attained prior to exhaustion in the test.  The 180 
GET was determined from a cluster of measurements including: 1) the first disproportionate 181 
increase in CO2 production ( co2) from visual inspection of individual plots of co2 vs. 182 
O2; 2) an increase in expired ventilation ( E) / O2 with no increase in E / co2; and 3) an 183 
increase in end-tidal O2 tension with no fall in end-tidal CO2 tension.  The data collected 184 
during the incremental tests were used to calculate cadence-specific work rates which were 185 
employed during the subsequent severe-intensity step tests.  Specifically, the work rates that 186 
would require 80% of the difference between the O2 at the GET and o2max (80%Δ) were 187 
estimated with account taken of the mean response time of the O2 response to ramp exercise 188 
(57). 189 
 190 
Step Exercise Tests 191 
Subjects completed one severe-intensity step test on days 4, 5, 8 and 9 of each dietary 192 
condition (PLA and BR).  The same pedal cadence (either 35 or 115 rpm) was applied on 193 
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days 4 and 5 of the supplementation period with the other cadence applied on days 8 and 9 of 194 
the supplementation period.  The order in which the 35 and 115 rpm tests were administered 195 
over the first supplementation period was randomised (3 subjects started on 35 rpm) and this 196 
order was replicated over the second supplementation period.  The step tests comprised 4 197 
minutes of baseline cycling at 20 W, followed by a step increment to a severe-intensity 198 
(80%∆) constant work rate that was continued until exhaustion (same criteria as described 199 
above for the incremental exercise test).  For each condition, the mean time to exhaustion was 200 
used for subsequent analysis. 201 
 202 
Supplementation Procedures 203 
Following the initial ramp tests, subjects underwent two 9-day supplementation periods with 204 
BR and PLA, with each period separated by at least ten-days of washout. Subjects recorded 205 
an 11-day food diary, which commenced two days prior to the first 9-day supplementation 206 
period, and were asked to use the diary to replicate and record their diet in the second 207 
supplementation period. The BR (Beet It Sport, James White Drinks, Ipswich, UK) was 208 
administered in 70 ml doses providing 6.2 mmol NO3
-
 per serving. Sodium chloride (NaCl) 209 
was administered as the PLA in doses of 0.1 mmol∙kg-1 body mass (41). Subjects were 210 
informed that the PLA was NaNO3, and that the purpose of the study was to compare the 211 
effects of ‘NaNO3’ relative to NO3
-
-rich BR. All labels and packaging were removed from 212 
the BR supplements and the PLA was provided in transparent plastic capsules which were 213 
placed in a small transparent plastic bag labelled sodium nitrate. Subjects were instructed to 214 
open the PLA capsules and mix the content with 200-300 ml of water for consumption. On 215 
days 1-3 and 6-7 of the supplementation periods (when no exercise tests were conducted), 216 
one dose of supplement was consumed in the morning and evening. On the days of the 217 
experimental testing (days 4-5 and 8-9), subjects were instructed to consume both supplement 218 
doses 2.5 hours before arriving at the laboratory (58).  An additional dose of supplement was 219 
consumed 2 hours following each experimental exercise test to counteract the marked 220 
depletion in plasma [NO2
-
] that occurs during intense exhaustive exercise (59). 221 
 222 
Measurements  223 
After reporting to the laboratory on days 4 and 8 of each dietary intervention (the first day 224 
that each cadence-specific step test was performed), a venous blood sample was drawn into a 225 
lithium-heparin tube and centrifuged at 4000 rpm and 4°C for 10 min, within 3 min of 226 
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collection.  Plasma was subsequently extracted and immediately frozen at -80°C for later 227 
analysis of [NO2
-
] in duplicate via ozone-based chemiluminescence (58). 228 
 229 
During all tests, pulmonary gas exchange and ventilation were measured breath-by-breath 230 
with subjects wearing a nose clip and breathing through a low-dead-space, low-resistance 231 
mouthpiece and impeller turbine assembly (Jaeger Triple V).  The inspired and expired gas 232 
volume and gas concentration signals were continuously sampled at 100 Hz, the latter using 233 
paramagnetic (O2) and infrared (CO2) analyzers (Jaeger Oxycon Pro, Hoechberg, Germany) 234 
via a capillary line connected to the mouthpiece.  The gas analyzers were calibrated before 235 
each test with gases of known concentration and the turbine volume transducer was calibrated 236 
with a 3-liter syringe (Hans Rudolph, Kansas City, MO).  The volume and concentration 237 
signals were time-aligned by accounting for the delay in the capillary gas transit and the 238 
analyzer rise time relative to the volume signal.  Pulmonary gas exchange and ventilation 239 
were calculated and displayed breath-by-breath. 240 
 241 
HR, SV and ?̇? data were recorded beat-by-beat using thoracic impedance cardiography 242 
(PhysioFlow PF-05; Manatec Biomedical, Paris, France) on days 4 and 8 of each dietary 243 
intervention.  The PhysioFlow measures impedance to a high-frequency (75 kHz), low-244 
magnitude (3.8 mA) alternating electrical current applied across the thorax and subsequently 245 
estimates SV based on changes in impedance over the cardiac cycle.  The current was 246 
transmitted through two electrodes placed superior to the supraclavicular fossa on the left 247 
lateral triangle of the neck and detected through two electrodes placed on the xiphoid process.  248 
To acquire an electrocardiogram (ECG) signal, two additional electrodes were placed at the 249 
V1 and V6 positions.  Body surface area was estimated using the Haycock formula (32) 250 
which, along with estimated SV and ECG-derived HR, was used to calculate ?̇?.  The 251 
PhysioFlow method and calculations have been described previously (15) and, when 252 
compared to the direct Fick method, the PhysioFlow has been shown to provide a valid 253 
estimate of ?̇? during exhaustive exercise (50).  All of the relevant skin sites were treated with 254 
an abrasive skin gel and alcohol prior to the application of the electrodes (Blue Sensor R; 255 
Ambu, Ballerup, Denmark), and leads were secured to the subjects using an adhesive tape.  256 
Following the application of the electrodes, subject rested for 10 min on the cycle ergometer.  257 
Four resting blood pressure measurements were taken using an automated 258 
sphygmomanometer (Dinamap Pro, GE Medical Systems, Tampa, FL) with the arm 259 
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supported at the level of the heart.  The mean of the final 3 measurements was recorded.  The 260 
PhysioFlow device was auto-calibrated prior to exercise using the manufacture’s software 261 
that gathered impedance waveforms throughout 30 cardiac cycles.  Following the test, data 262 
were downloaded onto a personal computer for subsequent analysis.  263 
 264 
The oxygenation status of the m. vastus lateralis of the right leg was monitored using a 265 
commercially available NIRS system (model NIRO 300, Hamamatsu Photonics KK, 266 
Hiugashi-ku, Japan) on days 4 and 8 of each dietary intervention.  The system consisted of an 267 
emission probe that irradiates laser beams and a detection probe.  Four different wavelength 268 
laser diodes provided the light source (776, 826, 845, and 905 nm) and the light returning 269 
from the tissue was detected by a photomultiplier tube in the spectrometer.  The intensity of 270 
incident and transmitted light was recorded continuously at 2 Hz and used to estimate 271 
concentration changes from the resting baseline for oxygenated, deoxygenated, and total 272 
tissue hemoglobin/myoglobin.  Therefore, the NIRS data represent a relative change based on 273 
the optical density measured in the first datum collected.  The deoxygenated 274 
hemoglobin/myoglobin concentration ([HHb]) signal was assumed to provide an estimate of 275 
changes in fractional O2 extraction in the field of interrogation (25, 27, 36).  It should be 276 
noted here that the contribution of deoxygenated myoglobin to the NIRS signal is presently 277 
unclear, and, as such, the terms [O2Hb], and [HHb] used in this paper should be considered to 278 
refer to the combined concentrations of oxygenated and deoxygenated hemoglobin and 279 
myoglobin, respectively.   280 
 281 
The leg was initially cleaned and shaved around the belly of the muscle, and the optodes were 282 
placed in the holder, which was secured to the skin with adhesive at 20 cm above the fibular 283 
head.  To secure the holder and wires in place, an elastic bandage was wrapped around the 284 
subject’s leg.  The wrap helped to minimize the possibility that extraneous light could 285 
influence the signal and also ensured that the optodes did not move during exercise.  Indelible 286 
pen marks were made around the holder to enable precise reproduction of the placement in 287 
subsequent tests.  The probe gain was set with the subject at rest in a seated position with the 288 
leg extended at down stroke on the cycle ergometer before the first exercise bout, and NIRS 289 
data were collected continuously throughout the exercise protocols.  The data were 290 
subsequently downloaded onto a personal computer, and the resulting text files were stored 291 
for later analysis. 292 
 293 
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Fingertip capillary blood samples (~20μl) were collected during the final 30 seconds of 294 
baseline cycling and at exhaustion. Blood [lactate] was determined using an automated 295 
analyser (YSI 2300, Yellow Springs Instruments, Yellow Springs, OH, USA). The mean of 296 
the two baseline and exhaustion blood [lactate] values were calculated for each experimental 297 
condition prior to analysis. Blood [lactate] accumulation during exercise was taken as the 298 
change in the values from baseline to exhaustion. 299 
 300 
Data Analysis Procedures 301 
The breath-by-breath O2 data from each test were initially examined to exclude errant 302 
breaths caused by coughing, swallowing, sighing, etc., and those values lying more than four 303 
standard deviations from the local mean were removed.  The breath-by-breath data were 304 
subsequently linearly interpolated to provide second-by-second values and, for each
 
305 
individual, the two identical repetitions for each experimental condition were time-aligned to 306 
the start of exercise and ensemble-averaged.  The first 20 s of data after the onset of exercise 307 
(i.e., the
 
phase I response) were deleted and a nonlinear least-square
 
algorithm was used to fit 308 
the data thereafter until the point of exhaustion.  A bi-exponential model was used to 309 
characterize the O2 responses to severe exercise, as described in the following equation:  310 
  311 
O2 (t) = O2 baseline + Ap(1-e
- (t-TDp/τp)
) + As(1-e
- (t-TDs/τs)
)            (Eqn. 2) 312 
 313 
where O2 (t) represents
 
the absolute O2 at
 
a given time t; O2baseline represents the mean 314 
O2
 
in the baseline period; Ap, TDp, and p represent the amplitude,
 
time delay, and time 315 
constant, respectively, describing the
 
phase II increase in O2 above baseline; and As, TDs, 316 
and s represent the
 
amplitude of, time delay before the onset of, and time constant describing 317 
the development
 
of, the O2 slow component,
 
respectively.   318 
 319 
An iterative process was used to minimize the
 
sum of the squared errors between the fitted 320 
function and the
 
observed values.  O2baseline
 
was defined as the mean O2 measured over the 321 
final 90 s of the resting baseline period.  The O2 at the limit of tolerance (Tlim) was defined 322 
as the mean O2 measured over the final 30 s of the exhaustive exercise bout.  Because the 323 
asymptotic value (As) of the exponential
 
term describing the O2
 
slow component may 324 
represent a higher value than is actually
 
reached at the end of the exercise, the actual 325 
amplitude of
 
the O2 slow component
 
at exhaustion was defined as As'.   326 
 327 
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The beat-by-beat HR, SV and ?̇? data from each test were averaged into 5-s bins prior to 328 
analysis.  To determine the overall kinetics (the mean response time [MRT]) of the central 329 
cardiovascular
 
responses, the data were fit with a mono-exponential model from 0-s to 330 
exhaustion without time delay using the following equation:   331 
 332 
Y (t) = Y baseline + A(1-e
- (t-/MRT)
)                                         (Eqn. 3) 333 
 334 
where Y (t) represents
 
the absolute value of the parameter of interest at
 
a given time t; Y 335 
baseline represents the mean value of the parameter of interest in the baseline period; A and 336 
MRT represent the amplitude and mean response time, respectively, describing the
 
increase 337 
in Y above baseline. 338 
 339 
To provide information on muscle oxygenation, we also modelled the [HHb] response to 340 
exercise. A mono-exponential model was applied to the data with the fitting window 341 
commencing at the time at which the [HHb] signal increased 1 SD above the baseline mean.  342 
The [HHb] kinetics were determined by constraining the fitting window to the point at which 343 
mono-exponentiality became distorted, consequent to a [HHb] slow component, as 344 
determined by visual inspection of the residual plots.  The [HHb] TD and τ values were 345 
summed to provide information on the overall [HHb] response dynamics in the fundamental 346 
phase of the response.   347 
 348 
The [O2Hb] response does not approximate an exponential and was, therefore, not modelled.  349 
Rather, we determined the [O2Hb] at baseline (90-s preceding step transition), 120 s (30 s 350 
mean surrounding 120 s) and exhaustion (mean response over the final 30 s of exercise).  The 351 
muscle [HHb] and [O2Hb] responses were summed at these time points ([Hbtot]) to provide 352 
information on the total [Hb] in the NIRS area of interrogation.     353 
 354 
Statistics 355 
A two-way, treatment (PLA and BR) × cadence (35 and 115 rpm), repeated-measures 356 
ANOVA was employed to assess differences in plasma [NO2
-
], O2 kinetics, HR, SV, ?̇?, 357 
muscle [HHb], muscle [O2Hb], muscle [Hbtot] and exercise tolerance across the experimental 358 
conditions.  Significant effects were further explored using post-hoc t-tests with the alpha 359 
level adjusted via a Fisher’s LSD correction.  Relationships between the outcome variables 360 
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were assessed using Pearson’s correlation coefficient (r).  Data are presented as mean ± SD, 361 
unless otherwise stated.  Statistical significance was accepted when P<0.05. 362 
 363 
Results 364 
 365 
The PLA and BR supplements administered in this study were well tolerated by all subjects 366 
with no negative side effects reported.  Subjects consumed all doses of the supplement for 367 
each experimental condition and their diet was consistent across all the dietary interventions.  368 
After all experimental testing for the study was completed, all subjects confirmed that they 369 
were unaware that the PLA condition was not NaNO3.  370 
 371 
The O2peak and peak work rate attained in the ramp incremental tests at 35 rpm and 115 rpm 372 
were, respectively, 3.84 ± 0.57 L·min
-1
 and 4.11 ± 0.56 L·min
-1
, and 304 ± 43 W and 319 ± 373 
52 W.  The O2 and work rate at the GET during the incremental tests were 1.62 ± 0.31 374 
L·min
-1
 and 122 ± 18 W at 35 rpm, and 2.53 ± 0.33 L·min
-1
 and 122 ± 8 W at 115 rpm, 375 
respectively.  There were no significant differences in O2peak or peak work rate attained 376 
during the ramp tests at 35 rpm and 115 rpm.  However, the O2 at the GET was significantly 377 
greater during the 115 rpm incremental test than the 35 rpm incremental test (P<0.001).  The 378 
work rates which corresponded to 80% Δ, which were imposed during the experimental tests 379 
conducted at 35 rpm and 115 rpm, were 244 ± 35 W and 258 ± 47 W, respectively.  These 380 
work rates were not significantly different from each other (P>0.05). 381 
 382 
Plasma [NO2
-
] and Blood Pressure 383 
There was a significant main effect for supplement on plasma [NO2
-
] (P<0.01), systolic blood 384 
pressure (SBP; P<0.05) and mean arterial pressure (MAP; P<0.05), but not diastolic blood 385 
pressure (DBP; P>0.05).  Plasma [NO2
-
] was significantly higher in both 35-BR and 115-BR 386 
compared to 35-PLA and 115-PLA (P<0.01), with plasma [NO2
-
] increased by 179% above 387 
PLA conditions with BR when all data were pooled (P<0.01; Figure 1).  There were no 388 
differences in plasma [NO2
-
] between 35-PLA and 115-PLA, and 35-BR and 115-BR 389 
(P>0.05).  Systolic blood pressure and mean arterial pressure were lowered by 8 mmHg and 4 390 
mmHg across the BR conditions when all data were pooled (P<0.05).      391 
 392 
 393 
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O2 Kinetics  394 
Pulmonary O2 at designated time points and the key parameters derived from the bi-395 
exponential modelling are presented in Table 1 and illustrated for a representative individual 396 
in Figure 2.  There was a significant main effect for cadence on O2 baseline and the O2 at 397 
120 s and exhaustion (P<0.01) with O2 at these time points being higher in both 115-PLA 398 
and 115-BR compared to both 35-PLA and 35-BR (P<0.05; Table 1).  The O2 at exhaustion 399 
was not significantly between 35-PLA and 35-BR and these values were not different to the 400 
O2peak attained in the incremental test at 35 rpm (P>0.05).  Likewise, the O2 at exhaustion 401 
in 115-PLA and 115-BR and the O2peak attained in the incremental test at 115 rpm were not 402 
significantly different from each other (P>0.05).  However, the O2 at exhaustion was higher 403 
in 115-PLA relative to 35-PLA and 115-BR relative to 35-BR (both P<0.01).  There was a 404 
significant main effect for cadence on the O2 phase II τ with a higher O2 phase II τ (slower 405 
O2 kinetics) in 115-PLA (61 ± 25 s) and 115-BR (47 ± 16 s) compared to both 35-PLA (32 406 
± 10 s) and 35-BR (32 ± 6 s; P<0.05; Table 1).  In addition there was a significant treatment 407 
× cadence interaction effect on the O2 phase II τ (P<0.05).  Post hoc analyses demonstrated 408 
that there was no significant difference in the O2 phase II τ between 35-PLA and 35-BR 409 
(P>0.05), but the O2 phase II τ was lower in 115-BR compared to 115-PLA (P<0.05; Table 410 
1; Figure 2).  There were no significant between-supplement differences in the O2 411 
fundamental amplitude (P>0.05), but there were significant between-cadence differences in 412 
the O2 fundamental amplitude (P<0.05; Table 1).  The O2 slow component amplitude was 413 
not significantly different between any of the experimental conditions (P<0.05; Table 1).             414 
 415 
Central Cardiovascular Parameters 416 
There were no significant between-supplement differences in HR, SV or ?̇? at baseline, 120 s 417 
or exhaustion (P>0.05 Table 2); however, there was a trend towards a main effect for cadence 418 
on the HR (P=0.071) and ?̇? (P=0.079) MRT.  Indeed, the HR MRT tended to be lower in 35-419 
PLA and 35-BR compared to both 115-PLA and 115-BR (P=0.07-0.08), but the HR MRT 420 
was not significantly different within cadences (P>0.05).  The ?̇? MRT was lower in 35-PLA 421 
and 35-BR compared to 115-PLA (P<0.05) with no differences between the other 422 
experimental conditions.         423 
 424 
 425 
 426 
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Muscle Oxygenation Parameters 427 
NIRS-derived [HHb], [O2Hb] and [Hbtot] responses are presented in Table 3 with group mean 428 
[HHb] and [O2Hb] responses illustrated in Figures 3 and 4, respectively.  There were no 429 
significant main effects or interaction effects on the [HHb] at baseline or throughout the step 430 
exercise test (P>0.05; Table 3).  The ANOVA revealed a significant main effect of 431 
supplement on the [HHb] τ + TD (P<0.05) and a significant main effect of cadence on the 432 
[HHb] amplitude (P<0.05; Table 3; Figure 3).  There were no significant differences in these 433 
variables across the individual experimental conditions (P>0.05).  There were significant 434 
main effects of cadence and a significant treatment × cadence interaction effect on the [O2Hb] 435 
at baseline, 120 s and at exhaustion (P<0.05).  Further analyses revealed that the [O2Hb] was 436 
greater in 115-BR at baseline compared to 115-PLA, at 120 s compared to all other 437 
conditions and at exhaustion compared to 35-PLA and 35-BR (P<0.05).  There were no 438 
significant main or interaction effects on [Hbtot]. 439 
 440 
Exercise Tolerance 441 
The effects of BR on Tlim at 35 rpm and 115 rpm are illustrated in Figure 5.  442 
Supplementation with BR significantly increased Tlim when cycling at 115 rpm (115-PLA: 443 
297 ± 79 s vs. 115-BR: 362 ± 137 s; P<0.05), but did not significantly alter Tlim at 35 rpm 444 
(35-PLA: 341 ± 99 s vs. 35-BR: 344 ± 74 s; P>0.05; Figure 5).  There was a significant 445 
correlation between the change in Tlim and muscle [O2Hb] at 120 s in 115-BR compared to 446 
115-PLA (r = 0.76, P<0.05) and a trend for a correlation between the change in muscle 447 
[O2Hb] at Tlim and the change in Tlim in 115-BR compared to 115-PLA (r = 0.76, P=0.07).  448 
There were no other correlations between the physiological and performance variables 449 
assessed in this study (P>0.05).       450 
 451 
Discussion 452 
The principal novel findings from this study are that short term dietary NO3
-
 supplementation, 453 
which enhanced the potential for O2-independent NO synthesis by elevating plasma [NO2
-
], 454 
increased muscle oxygenation, speeded phase II O2 kinetics and improved severe-intensity 455 
exercise tolerance (Tlim) when cycling at 115 rpm.  In contrast, there were no changes in 456 
muscle oxygenation, O2 kinetics or exercise tolerance with BR at 35 rpm.  There were no 457 
changes in ?̇? with BR at either cadence, but muscle [O2Hb] was higher in 115-BR compared 458 
to 115-PLA.  These findings suggest that BR increased muscle O2 delivery at 115 rpm 459 
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facilitating faster phase II O2 kinetics and improved severe-intensity exercise tolerance.  460 
This is consistent with our experimental hypothesis and suggests that BR supplementation is 461 
more effective at improving muscle O2 delivery, phase II O2 kinetics and fatigue resistance 462 
at higher pedal cadences.     463 
 464 
In line with other studies administering NO3
-
-rich BR (3-4, 12, 40-41, 55, 58), plasma [NO2
-
] 465 
was increased in this study.  Importantly, plasma [NO2
-
] was not significantly different 466 
between the 2 BR trials and between the 2 PLA trials.  This observation is consistent with our 467 
previous finding that plasma [NO2
-
] remains consistently elevated above baseline with BR, at 468 
least up to 15 days of supplementation (55).  An increase in the circulating plasma [NO2
-
] 469 
reflects an increase in the reserve for NOS-independent NO production given that NO2
-
 470 
undergoes a simple one-electron reduction to NO through numerous NO2
-
 reductatses (42, 471 
54).  The reduction of NO2
-
 to NO is upregulated as O2 tension (14) and pH (45) decline and, 472 
since muscle PO2 (51) and pH (3) are lowered during intense muscle contractions, NO2
-
 473 
reduction is likely to be an important source of NO during exercise.  Aside from its reduction 474 
to NO, it should be acknowledged that NO2
-
 itself can participate in post-translational protein 475 
modifications that positively impact on physiological processes (2).  Moreover, a few days of 476 
NO3
-
 supplementation can increase mitochondrial (40) and calcium-handling (33) proteins 477 
promoting enhanced metabolic and contractile function, respectively.  Therefore, the short 478 
term exposure to inorganic NO3
-
 and the associated increase in plasma [NO2
-
] in this study 479 
may have been sufficient to increase NO signalling and elicit favorable physiological and 480 
functional responses.  Indeed, resting arterial blood pressure was lowered by BR 481 
supplementation in this study, in accord with established effects of elevated NO on vascular 482 
tone (28).   483 
 484 
Pulmonary O2 was significantly higher at baseline and throughout exercise when cycling at 485 
115 rpm compared to 35 rpm, as reported previously (19, 25, 60).  While subjects were 486 
cycling at the same external work rate at baseline (20 W), and the same relative exercise 487 
intensity (80%Δ) during the step tests, internal work (56) and muscle ATP turnover rate and 488 
O2 (22) are increased at higher contraction frequencies, which accounts for the higher 489 
pulmonary O2 observed in the 115 rpm trials.  The phase II O2 τ was higher ( O2 kinetics 490 
was slower) when cycling at 115 rpm than 35 rpm, which corroborates findings of a slower 491 
adjustment of O2 when cycling at a higher pedal cadence (11, 19).   492 
 493 
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In concert with slower phase II O2 kinetics, there was a trend for slower ?̇? kinetics in the 494 
115 rpm trials, suggesting that the slower O2 kinetics might have been related to a slower 495 
adjustment of bulk blood flow and O2 delivery to the contracting muscles in the higher 496 
cadence condition.  However, there is strong evidence that bulk muscle blood flow is 497 
enhanced at higher contraction frequencies (22, 30, 47, 52).  Despite slower phase II O2 498 
kinetics at the higher pedal cadence, there were no differences in muscle microvascular 499 
[HHb] kinetics (τ + TD) between 115 rpm and 35 rpm.  Since muscle [HHb] is considered a 500 
non-invasive proxy for muscle O2 extraction (25, 36), this suggests that the slower phase II 501 
O2 kinetics at 115 rpm might be a function of slower microvascular blood flow kinetics and, 502 
therefore, to a relative shortfall in muscle O2 delivery compared to muscle O2 demand over 503 
the initial stages of the severe-intensity step test.  The slower phase II O2 kinetics at the 504 
higher pedal cadence might also reflect increased fast-twitch fiber recruitment (7), because 505 
fast-twitch fibers are believed to exhibit slower O2 kinetics (18, 39).  Alternatively, the 506 
higher baseline metabolic rate that is elicited by cycling at a higher pedal cadence might have 507 
slowed phase II O2 kinetics due to the altered energetic state (9, 12).     508 
 509 
Supplementation with BR did not significantly impact HR, SV, ?̇?, muscle oxygenation or 510 
O2 kinetics when cycling at 35 rpm in this study.  Conversely, phase II O2 kinetics was 23% 511 
faster in 115-BR than 115-PLA.  The faster O2 kinetics in 115-BR was not a function of 512 
enhanced HR, SV or ?̇?, as these were similar in 115-BR and 115-PLA.  However, muscle 513 
[O2Hb] was increased at baseline and throughout exercise in 115-BR compared to 115-PLA 514 
suggesting that the faster phase II O2 kinetics in 115-BR might have been linked to 515 
increased delivery of O2 to the muscle microvasculature.  Since the slower O2 kinetics in the 516 
115 rpm trials compared to the 35 rpm trials appears to be linked to slower muscle O2 517 
delivery (as described above), the increase in muscle O2 delivery at the higher cadence with 518 
BR might have partly corrected for the compromised muscle O2 delivery permitting faster 519 
O2 kinetics in 115-BR compared to 115-PLA.  This interpretation is in keeping with the O2 520 
tipping point theory proposed by Poole and Jones (48), which stipulates that phase II O2 521 
kinetics is only speeded by interventions which enhance muscle O2 delivery when muscle O2 522 
delivery is initially limited, at least in healthy adults.   523 
 524 
A more rapid adjustment in oxidative metabolism following the onset of exercise would be 525 
expected to spare the utilization of the finite anaerobic energy reserves and attenuate the 526 
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accumulation of fatigue-related metabolites, thereby promoting enhanced exercise tolerance 527 
(13, 35).  This is supported by our observation that exercise tolerance was enhanced by ~22% 528 
when phase II O2 kinetics was speeded by BR (i.e., at 115 rpm where the phase II τ was 529 
~23% shorter after supplementation) and unchanged when no speeding was present (i.e., at 530 
35 rpm; see figure 5).  Furthermore, the improvements in exercise tolerance and muscle 531 
[O2Hb] at 120 s with BR at 115 rpm were significantly correlated.  This suggests that the 532 
increase in muscle O2 delivery with BR was an important contributor to the ergogenic effects 533 
of BR at 115 rpm.  Plasma [NO2
-
] was increased with BR and since NO2
-
 can positively 534 
impact on vascular function directly (2), or indirectly through its reduction to NO (28, 42, 535 
54), this is likely to account for the improved muscle O2 delivery with BR.  Indeed, previous 536 
studies have shown that NO3
-
 supplementation can increase muscle blood flow in the running 537 
rat (23) and that NO2
-
 infusion can increase blood flow in humans completing forearm 538 
exercise (17).  The potential for enhanced perfusion with BR is likely to be more pronounced 539 
in the microvasculature of fast-twitch muscle, where PO2 during contractions is lower (8, 44), 540 
since the reduction of NO2
-
 to NO is augmented as PO2 declines (14).  This might explain why 541 
NO3
-
 supplementation has been shown to preferentially distribute blood flow towards the 542 
more fatigue-susceptible fast-twitch muscle fibers in rats (23) and to speed phase II O2 543 
kinetics when a greater proportion of fast-twitch muscle fibers are likely to be recruited (12).  544 
Therefore, assuming the recruitment of fast-twitch muscle was greater at the higher cadence 545 
(6-7, but see 1), this might account for the increased muscle [O2Hb] in 115-BR, but not 35-546 
BR, in this study.  This increased muscle O2 delivery in 115-BR likely reduced the mismatch 547 
between muscle O2 delivery and muscle O2 utilization at the higher pedal cadence which, in 548 
turn, promoted a more rapid adjustment of phase II O2 kinetics and improved exercise 549 
tolerance in 115-BR relative to 115-PLA.  Alternatively, or in conjunction with enhanced 550 
fast-twitch muscle perfusion, inorganic NO3
-
 supplementation has been shown to enhance 551 
calcium-handling proteins in fast-twitch muscle and to increase cytoplasmic [calcium] (33).  552 
This might provide a greater stimulus for oxidative phosphorylation in fast-twitch muscle 553 
fibers, potentially promoting faster O2 kinetics in 115-BR (31).  It is also possible that the 554 
higher baseline metabolic rate evoked by the higher pedal cadence was responsible for the 555 
effects of BR at 115 rpm, but not 35 rpm, in this study (12).  Bowen et al. (9) suggested that 556 
elevating metabolic rate during cycling exercise negatively impacted the intramuscular 557 
energy state leading to slower phase II O2 kinetics.  Since NO3
-
 supplementation has been 558 
shown to blunt intramuscular adenosine diphosphate and inorganic phosphate accumulation, 559 
and phosphocreatine utilization during exercise (3), the faster O2 kinetics and improved 560 
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exercise tolerance in 115-BR might be linked to an improved intramuscular energy state, 561 
regardless of muscle fiber recruitment patterns, in the higher cadence condition.       562 
 563 
In addition to the faster phase II O2 kinetics in 115-BR, there is also evidence to 564 
demonstrate that NO3
-
 supplementation can increase force during the initial stages of high-565 
frequency maximal stimulation (29) and at high but not low contraction velocities (16) in 566 
human skeletal muscle in vivo.  Moreover, NO3
-
 supplementation can increase the rate of 567 
force development during high-frequency stimulation in mouse skeletal muscle in vitro (33).  568 
Taken together with the enhanced muscle oxygenation and faster phase II O2 kinetics 569 
observed in this study, these findings suggest that the effects of NO3
-
 supplementation on 570 
skeletal muscle vascular function, metabolism and force production are enhanced at higher 571 
contraction velocities and frequencies and that these positive physiological responses are 572 
likely to account for the improved fatigue resistance observed with BR at 115 rpm, but not 35 573 
rpm, in the current study.  The results of this study might have important implications for 574 
improving skeletal muscle fatigue resistance at a high muscle contractile frequency or 575 
velocity, when greater recruitment of type II muscle fibers and a lower contractile efficacy 576 
might be expected.   577 
 578 
In conclusion, short-term dietary supplementation with inorganic NO3
-
 increased muscle 579 
[O2Hb] during cycling at 115 rpm, without changing muscle [Hbtot], suggesting improved 580 
muscle oxygenation.  This increase in muscle oxygenation was accompanied by faster phase 581 
II O2 kinetics and was correlated with improved exercise tolerance in 115-BR.  There were 582 
no changes in muscle oxygenation, phase II O2 kinetics and exercise tolerance with BR 583 
when cycling at very slow pedal cadence (35 rpm).  Considered together, our findings suggest 584 
that NO3
-
 supplementation is more effective at improving muscle microvascular oxygenation, 585 
pulmonary O2 kinetics and exercise tolerance during cycle ergometry exercise when a 586 
higher pedal cadence is employed.  These findings might have important implications for 587 
speeding the adjustment of pulmonary O2 and improving fatigue resistance in exercise 588 
settings where more type II muscle fibers are recruited and/or muscle O2 delivery is 589 
compromised.       590 
 591 
 592 
 593 
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Figure Legends 858 
 859 
Figure 1:  Resting plasma nitrite concentration ([NO2
-
]) following placebo (PLA) and nitrate-860 
rich beetroot juice (BR) supplementation. The open bar represents the group mean ± SEM 861 
plasma [NO2
-
] from the PLA trials, while the filled bar represents the group mean ± SEM 862 
plasma [NO2
-
] from the BR trials.  The solid grey lines represent the individual changes in 863 
plasma [NO2
-
] following BR supplementation. * indicates significantly different from PLA 864 
(P<0.01).  Note the increase in plasma [NO2
-
] with BR supplementation. 865 
 866 
Figure 2: Pulmonary oxygen uptake ( O2) responses to a step increment from an unloaded 867 
baseline to a severe-intensity work rate in a representative subject.  The upper panel 868 
illustrates the O2 responses whilst cycling at a cadence of 35 rpm following placebo (PLA) 869 
and nitrate-rich beetroot juice (BR) supplementation.  The lower panel shows the O2 870 
responses whilst cycling at a cadence of 115 rpm following placebo (PLA) and nitrate-rich 871 
beetroot juice (BR) supplementation.  Data are expressed as a percentage of the O2 during 872 
baseline cycling and displayed as 5-s averages. The dashed vertical line indicates the point of 873 
the abrupt increase in work rate.  Note the more rapid increase in O2 with BR following the 874 
step increment in work rate at 115 rpm, but not 35 rpm.  Data are truncated at 180 s. 875 
 876 
Figure 3: Muscle deoxyhemoglobin concentration ([HHb]) group mean responses to a step 877 
increment from an unloaded baseline to a severe-intensity work rate.  The upper panel 878 
illustrates the [HHb] responses whilst cycling at a cadence of 35 rpm following placebo 879 
(PLA) and nitrate-rich beetroot juice (BR) supplementation.  The lower panel shows the 880 
[HHb] responses whilst cycling at a cadence of 115 rpm following placebo (PLA) and nitrate-881 
rich beetroot juice (BR) supplementation.  Data are expressed as the change in muscle [HHb] 882 
above baseline values and displayed as 5-s averages.  The dashed vertical line indicates the 883 
point of the abrupt increase in work rate.  Note the slower adjustment of muscle [HHb] 884 
following the step increment in work rate with BR for both conditions.  Data are truncated at 885 
180 s. 886 
 887 
Figure 4: Muscle oxyhemoglobin concentration ([O2Hb]) group mean responses to a step 888 
increment from an unloaded baseline to a severe-intensity work rate.  The upper panel 889 
illustrates the [O2Hb] responses whilst cycling at a cadence of 35 rpm following placebo 890 
(PLA) and nitrate-rich beetroot juice (BR) supplementation.  The lower panel shows the 891 
28 
 
[O2Hb] responses whilst cycling at a cadence of 115 rpm following placebo (PLA) and 892 
nitrate-rich beetroot juice (BR) supplementation.  Data are expressed as 5-s averages and the 893 
dashed vertical line indicates the point of the abrupt increase in work rate.  Note the 894 
significantly higher [O2Hb] during baseline cycling and during the severe-intensity cycling 895 
bout with BR at 115 rpm, but not 35 rpm. 896 
 897 
Figure 5: Time-to-exhaustion responses during a step increment from an unloaded baseline 898 
to a severe-intensity constant work rate. The upper panel compares time-to-exhaustion 899 
following placebo (PLA) and nitrate-rich beetroot juice (BR) supplementation whilst cycling 900 
at 35 rpm.  The lower panel compares time-to-exhaustion following placebo (PLA) and 901 
nitrate-rich beetroot juice (BR) supplementation whilst cycling at 115 rpm.  The open bars 902 
represent the group mean ± SEM responses after PLA supplementation, while the filled bars 903 
represent the group mean ± SEM responses after BR supplementation.  The solid grey lines 904 
represent the individual changes in time-to-exhaustion following BR supplementation. * 905 
indicates significantly different from PLA (P<0.05).  Note the significant increase in exercise 906 
tolerance after BR at 115 rpm, but not 35 rpm. 907 
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Table 1. Pulmonary oxygen uptake ( O2) measures during severe-intensity cycle exercise 924 
at 35 rpm and 115 rpm after placebo (PLA) and nitrate-rich beetroot juice (BR) 925 
supplementation. 926 
 927 
 35-PLA 35-BR 115-PLA 115-BR 
Oxygen Uptake ( O2)     
Baseline (L∙min-1) 0.92 ± 0.14  0.89 ± 0.07 1.93 ± 0.34*ɸ 1.89 ± 0.25*ɸ 
120 s (L∙min-1) 3.41 ± 0.55 3.45 ± 0.51 3.65 ± 0.49* ɸ 3.68 ± 0.47*ɸ 
Exhaustion (L∙min-1) 3.83 ± 0.58 3.86 ± 0.52 4.24 ± 0.61*ɸ 4.32 ± 0.75*ɸ 
Phase II τ (s) 32 ± 10 32 ± 6 61 ± 25*ɸ 47 ± 16*ɸΨ 
Fundamental amplitude (L∙min-1) 2.58 ± 0.40 2.61 ± 0.43 2.01 ± 0.24*ɸ 1.92 ± 0.30*ɸ  
Slow component amplitude (L∙min-1) 0.44 ± 0.15 0.35 ± 0.18 0.38 ± 0.32 0.53 ± 0.42 
Values are presented as the mean ± SD. * = significantly different from 35-PLA (P<0.05); ɸ = 928 
significantly different from 35-BR (P<0.05); Ψ = significantly different from 115-PLA 929 
(P<0.05). 930 
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Table 2. Heart rate (HR), stroke volume (SV) and cardiac output (?̇?) measures during 948 
severe-intensity cycle exercise at 35 rpm and 115 rpm after placebo (PLA) and nitrate-949 
rich beetroot juice (BR) supplementation. 950 
 35-PLA 35-BR 115-PLA 115-BR 
Heart Rate (HR)     
Baseline (beats∙min-1) 89 ± 10 88 ± 11 124 ± 19*ɸ 131 ± 21*ɸ 
120 s (beats∙min-1) 153 ± 15 153 ± 13 162 ± 17*ɸ 165 ± 13*ɸ 
Exhaustion (beats∙min-1) 168 ± 16 166 ± 15 178 ± 17*ɸ 178 ± 12*ɸ 
     
Stroke Volume (SV)     
Baseline (mL∙beat-1) 93 ± 6   87 ± 15 102 ± 14ɸ 98 ± 17 
120 s (mL∙beat-1) 108 ± 12 100 ± 19 111 ± 14 105 ± 11 
Exhaustion (mL∙beat-1) 102 ± 13 99 ± 16 111 ±  17  104 ± 13 
     
Cardiac Output (?̇?)     
Baseline (L∙min-1) 8 ± 1 8 ± 2 12 ± 2*ɸ 13 ± 4*ɸ 
120 s (L∙min-1) 16 ± 2 15 ± 4 18 ± 2 17 ± 3 
Exhaustion (L∙min-1) 17 ± 2 16 ± 4 20 ± 3ɸ 18 ± 2 
Values are presented as the mean ± SD. * = significantly different from 35-PLA (P<0.05); ɸ = 951 
significantly different from 35-BR (P<0.05);  952 
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Table 3. Near-infrared spectroscopy determined muscle oxyhemoglobin concentration 965 
([O2Hb]), deoxyhemoglobin concentration ([HHb]) and total hemoglobin concentration 966 
([Hbtot]) measures during severe-intensity cycle exercise at 35 rpm and 115 rpm after 967 
placebo (PLA) and nitrate-rich beetroot juice (BR) supplementation. 968 
 35-PLA 35-BR 115-PLA 115-BR 
Muscle [HHb]     
Baseline (A.U.) -4.0 ± 3.8 -3.9 ± 2.5 -2.0 ± 4.2 -3.0 ± 3.9 
120 s (A.U.) 5.8 ± 6.1 5.4 ± 5.8 4.3 ± 4.2 2.9 ± 5.9 
Exhaustion (A.U.) 6.4 ± 6.7 7.0 ± 7.0 4.9 ± 4.3 4.1 ± 6.5 
[HHb] τ  + TD (s) 19 ± 6 23 ± 13 24 ± 14 36 ± 24 
[HHb] amplitude (A.U.) 10 ± 5 9 ± 6 6 ± 4 6 ± 3 
     
Muscle [O2Hb]     
Baseline (A.U.) 1.8 ± 3.1 0.1 ± 4.5 -1.1 ± 3.5* 3.4 ± 4.9Ψ 
120 s (A.U.) -6.9 ± 2.9 -7.7 ± 7.1 -6.1 ± 3.7 -1.0 ± 6.3*ɸΨ 
Exhaustion (A.U.) -6.9 ± 3.1 -7.0 ± 6.7 -6.0 ± 5.4  -0.6 ± 7.8*ɸ 
     
Muscle [Hbtot]     
Baseline (A.U.) -2.2 ± 3.2 -3.8 ± 6.4 -3.1 ± 3.1 0.3 ± 5.5 
120 s (A.U.) -1.1 ± 5.9  -2.3 ± 8.1 -1.8 ± 3.2 1.9 ± 5.5 
Exhaustion (A.U.) -0.5 ± 5.7 -0.1 ± 8.9 -1.2 ± 4.3 3.5 ± 7.0 
Values are presented as the mean ± SD. * = significantly different from 35-PLA (P<0.05); ɸ = 969 
significantly different from 35-BR (P<0.05); Ψ = significantly different from 115-PLA 970 
(P<0.05). A.U., arbitrary units. 971 
 972 
0 
100 
200 
300 
400 
500 
PLA BR 
P
la
sm
a 
[N
O
2
- ]
 (
n
M
) 
Fig 1 
* 
100 
140 
180 
220 
260 
300 
340 
380 
420 
-60 0 60 120 180 
100 
120 
140 
160 
180 
200 
220 
-60 0 60 120 180 
Time (s) 
P
u
lm
o
n
a
ry
 O
x
y
g
e
n
 U
p
ta
k
e
 (
%
 B
a
s
e
li
n
e
) 
P
u
lm
o
n
a
ry
 O
x
y
g
e
n
 U
p
ta
k
e
 (
%
 B
a
s
e
li
n
e
) 
Fig 2 
115-PLA 
115-BR 
35-PLA 
35-BR 
0 
2 
4 
6 
8 
10 
12 
-60 0 60 120 180 
0 
2 
4 
6 
8 
-60 0 60 120 180 
Fig 3 
115-PLA 
115-BR 
35-PLA 
35-BR 
Δ
 M
u
s
c
le
 [
H
H
b
] 
(A
.U
.)
 
Δ
 M
u
s
c
le
 [
H
H
b
] 
(A
.U
.)
 
-8 
-6 
-4 
-2 
0 
2 
4 
6 
8 
-60 0 60 120 180 
-8 
-6 
-4 
-2 
0 
2 
4 
6 
8 
-60 0 60 120 180 
Time (s) Fig 4 
115-PLA 
115-BR 
35-PLA 
35-BR 
M
u
s
c
le
 [
O
2
H
b
] 
(A
.U
.)
 
M
u
s
c
le
 [
O
2
H
b
] 
(A
.U
.)
 
100 
200 
300 
400 
500 
600 
700 
35-PLA 35-BR 
100 
200 
300 
400 
500 
600 
700 
115-PLA 115-BR 
Fig 5 
* 
T
im
e
 t
o
 E
x
h
a
u
s
ti
o
n
 (
s
) 
T
im
e
 t
o
 E
x
h
a
u
s
ti
o
n
 (
s
) 
